β-globin DNA in maternal plasma as a molecular marker of pre-eclampsia
β-globin DNA in maternal plasma as a molecular marker of pre-eclampsia
复制标题
DOI：
10.1002/pd.965
复制
发表时间：
2004-09-01
影响因子：
3
通讯作者：
Okai, T
中科院分区：
文献类型：
--
作者：
Sekizawa, A;Farina, A;Okai, T
目的在先兆子痫（PE）的临床特征存在下，母体血浆中无细胞胎儿DNA的水平较高。然而，目前，该方法仅在携带男性胎儿的女性中通过扩增Y特异性序列提供信息。在本研究中，我们克服了这一限制，通过检查β-珠蛋白，胎儿性别无关的DNA marker.Methods的定量分布，我们定量β-珠蛋白浓度在血浆中的207名孕妇：对照组，164名受试者，受影响的组，43名妇女受PE（n = 43）。β-珠蛋白浓度被转换成对照组中位数（MoM）的倍数，以评估β-珠蛋白MoM在病例组和对照组中可能的不同分布。结果调整后的MoM值如下：对照组，1.00 +/- 0.71;患病组4.03 +/- 3.77（P值< 0.001）。在PE患者中，胎儿生长受限（FGR）患者的MoM β-珠蛋白值几乎是无FGR患者的2倍（p值= 0.003）。结论PE患者血浆β-珠蛋白水平较高，尤其是合并FGR的患者，且与胎儿性别无关。这样的分子标记物可以潜在地用于评估PE的病理生理严重性。版权所有（C）2004约翰威利父子有限公司。
Objectives Levels of cell-free foetal DNA in maternal plasma are higher in the presence of clinical features of pre-eclampsia (PE). However, currently, this method is informative only in women bearing a male foetus, by amplification of Y-specific sequences. In the present study, we overcame this limitation by examining quantitative distribution of beta-globin, a foetal gender- independent DNA marker.Methods We quantified beta-globin concentrations in the plasma of 207 pregnant women: control group, 164 subjects; affected group, 43 women affected by PE (n = 43). beta-globin concentrations were converted into multiples of the median of the controls (MoM), in order to assess the possible different distribution of beta-globin MoM in cases and controls.Results Adjusted MoM values were as follows: controls, 1.00 +/- 0.71; affected group 4.03 +/- 3.77 (P-value < 0.001). Among the PE affected cases, MoM beta-globin values of cases with foetal growth restriction (FGR) were almost twice as great as those cases without FGR (p-value = 0.003).Conclusion beta-globin levels are higher in the plasma of pregnant women with PE, especially in those cases complicated with FGR, and do not depend on foetal gender. Such a molecular marker can potentially be used in evaluating the pathophysiological severity of PE. Copyright (C) 2004 John Wiley Sons, Ltd.